Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Multi-Center Clinical Study Intensifies First Strike at High-Risk Cancer in Kids

13.06.2012
An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma – a deadly, hard-to-cure childhood cancer.

The experimental radiopharmaceutical, 131I-MIBG, has already been tested in children with relapsed and resistant neuroblastoma, with encouraging results in reducing tumor size. This has prompted doctors in a new multi-center pilot clinical trial to see if their innovative combination therapy can help improve cure rates for newly diagnosed children and young adults, according to Brian Weiss, MD, trial chair and an oncologist at the Cincinnati Children’s Hospital Medical Center.

Cure rates for neuroblastoma have plateaued at about 40 percent and new solutions are needed to improve outcomes, said Weiss, a member of the medical center’s Cancer and Blood Diseases Institute.

“Unlike some diseases, there is no single detectable biological sign of neuroblastoma, so it’s hard to catch early,” he explained. “Children with relapsed disease usually don’t survive more than a few years. We want to see if giving this more intensive treatment right after diagnosis will safely decrease the chances of the cancer coming back.”

Neuroblastoma is one of the most commonly diagnosed childhood cancers, developing in nerve cells outside the brain. The cancer is usually first diagnosed by showing up as a lump or mass in the belly, or near the spinal cord in the chest or neck. The disease can spread to bone, the liver, lymph nodes and bone marrow. In high-risk neuroblastoma, the tumor has often spread from its primary site and is harder to treat.

MIBG stands for Meta-Iodo-Benzyl-Guanidine, a synthesized form of the adrenal gland hormone and neurotransmitter adrenalin. MIBG concentrates selectively in the body’s sympathetic nervous system, which helps control glands and muscles. When attached to the radioactive isotope iodine-131, it’s known as 131I-MIBG. After being injected, 131I-MIBG targets and is taken up by nerve tumors like neuroblastoma. This exposes the cancer cells to very high doses of radiation from the iodine-131, with minimal toxicity to neighboring normal cells.

Standard treatment for neuroblastoma normally includes several rounds of chemotherapy combined with surgery and external radiation. In the current trial, a round of chemotherapy will be replaced by injection of 131I-MIBG combined with the chemotherapy drugs vincristine and irinotecan. The chemotherapy drugs will kill some of the cancer cells and, according to research, may help 131I-MIBG do a better job of eradicating tumor cells, said Weiss.

Patients receiving the treatment will also receive a transfusion of previously collected blood stem cells to boost their blood counts after being injected with the radioactive isotope.

The trial is coordinated through and sponsored by the Children’s Oncology Group (COG), an international research consortium of the National Cancer Institute (National Institutes of Health). Thirteen hospitals in the United States and Canada are currently participating in the trial, which is expected to last two years and include up to 44 newly diagnosed patients who have not received previous treatment for their neuroblastoma.

Data from the trial, considered a small pilot study, will be used to help inform larger subsequent clinical trials testing 131I-MIBG-vincristine-irinotecan therapy for neuroblastoma, according to Weiss. The pilot trial’s initial goal is determining the feasibility of newly diagnosed patients traveling from a participating home/regional medical center to participating specialized centers that will administer the 131I-MIBG part of therapy, and then back to their home center for the remainder of treatment.

Four of the 13 currently participating hospitals will administer the 131I-MIBG portion of the therapy, which requires special capabilities: Cincinnati Children’s, Children’s Hospital of Philadelphia, University of California-San Francisco School of Medicine, and C.S. Mott Children’s Hospital in Ann Arbor, Mich.

Other participating hospitals include: Phoenix Children’s Hospital, Medical University of Southern Carolina, University of Texas Southwestern Medical Center, Children’s Hospital Los Angeles, The Children’s Hospital Denver, Children’s National Medical Center, Primary Children’s Medical Center, Salt Lake City, University of Chicago, and University of Alabama, Birmingham. Two additional medical centers are expected to be added to the trial, Weiss said.

For more information, contact the Cincinnati Children’s Cancer and Blood Diseases Institute at 513-636-2799 or cancer@cchmc.org,or visit: http://clinicaltrials.gov/ct2/show/NCT01175356?term=MIBG&rank=13.

For more information about neuroblastoma therapies and research at the Cincinnati Children’s Cancer and Blood Diseases Institute, please visit: http://www.cincinnatichildrens.org/service/n/neuroblastoma/default/.

Contact Information
Nick Miller, 513-803-6035, nicholas.miller@cchmc.org

Nick Miller | EurekAlert!
Further information:
http://www.cchmc.org

More articles from Studies and Analyses:

nachricht Antarctic Ice Sheet mass loss has increased
14.06.2018 | Technische Universität Dresden

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

Im Focus: Photoexcited graphene puzzle solved

A boost for graphene-based light detectors

Light detection and control lies at the heart of many modern device applications, such as smartphone cameras. Using graphene as a light-sensitive material for...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Carbon nanotube optics provide optical-based quantum cryptography and quantum computing

19.06.2018 | Physics and Astronomy

How to track and trace a protein: Nanosensors monitor intracellular deliveries

19.06.2018 | Life Sciences

New material for splitting water

19.06.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>